New Risk • Jul 31
New major risk - Financial data availability The company's latest financial reports are more than a year old. Last reported fiscal period ended June 2025. This is considered a major risk. If the company has not reported its earnings on time, it may have been delayed due to audit problems or it may be finding it difficult to reconcile its accounts. In the worst case scenario, it may be facing other major going concern issues jeopardizing its viability as a listed company. Currently, the following risks have been identified for the company: Major Risks Latest financial reports are more than 1 year old (reported June 2025 fiscal period end). Shareholders have been substantially diluted in the past year (35% increase in shares outstanding). Minor Risks Revenue is less than US$5m (₩1.5b revenue, or US$1.1m). Market cap is less than US$100m (₩22.5b market cap, or US$15.6m). Announcement • Jul 02
Poongjeon Pharmacy CO.,LTD. announced that it has received KRW 3.99999812 billion in funding from Korea Investment & Securities Co., Ltd. On June 30, 2026, Poongjeon Pharmacy CO.,LTD. closed the transaction for the common shares tranche of the offering. The proceeds received KRW 1,999,998,120 from this tranche. Announcement • Jun 12
Poongjeon Pharmacy CO.,LTD. announced that it expects to receive KRW 3.99999812 billion in funding from Korea Investment & Securities Co., Ltd. and another investor.. Poongjeon Pharmacy CO., LTD announced a private placement to issue 796,812 common shares at an issue price of KRW 2510 per share for gross proceeds of KRW 1,999,998,120 on June 10, 2026. The transaction includes participation from new investor Cony New Technology Association No. 63. The transaction has been approved by shareholders, expected to close on June 30, 2026. The payment date of is June 30, 2026. Private placement issuance is subject to mandatory lockup for 1 year.
On the same date the company announced a private placement to issue series 3 unsecured convertible bonds for gross proceeds of KRW 2,000,000,000. The transaction will include participation from new investor, Korea Investment & Securities Co., Ltd. The bonds will carry an interest rate of 2% and will have a maturity interest rate of 2%. The bonds will mature on June 18, 2029. The bonds will be 100% convertible into 600,240 common shares of the company at a conversion price of KRW 3,332. The conversion period for the bonds will be between June 18, 2027 to May 18, 2029. The transaction has been approved by the board of directors of the company and is expected to close on June 18, 2026. The securities issued in the transaction will be held for a lockup period of 1 year. The payment date is June 18, 2026. 
